stars 1 stars 2 stars 3

At Biovotec we are working to shape the future of wound healing. By reducing the cost of advance wound care products, we offer an unrivaled advantage for both patients and clinicians. We believe that everybody should have access to affordable, advance wound care products. Generally the body has an amazing ability to heal itself. However, under some circumstances ulcers may form and wounds may heal slowly, becoming chronic. In these cases extensive treatment and medication are required and with a significantly increased healing time. In the worst cases healing times extend to several years and some may never truly heal. Biovotec is developing a series of next-generation, advanced wound care products based on a novel biomaterial derived from hen eggshell membrane. Thanks to a novel separation and purification process - exclusively available to Biovotec – functional biomaterials can now be produced based on native, unmodified eggshell membrane.

Biovotec Questions

The Biovotec annual revenue was $4 million in 2026.

Henri-Pierre Suso is the Co founder and CTO at Biovotec of Biovotec.

1 people are employed at Biovotec.

Biovotec is based in Oslo, Oslo.

The NAICS codes for Biovotec are [54171, 541, 541713, 54, 5417].

The SIC codes for Biovotec are [87, 873].

Top Biovotec Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users